MicroRNAs in Systemic Lupus Erythematosus: a Perspective on the Path from Biological Discoveries to Clinical Practice.
PURPOSE OF REVIEW
MicroRNAs (miRNAs) play essential roles in immune abnormalities and organ damage of systemic lupus erythematosus (SLE). Current findings have indicated potential clinical applications of miRNAs for combating SLE. Here, we review recent evidence which support the notions that miRNAs can be novel biomarkers and therapeutic agents for SLE.


RECENT FINDINGS
Following years of the studies of the expression patterns of miRNAs in both peripheral blood cells and body fluids, such as plasma and urine, several miRNAs or miRNA combinations have been associated with disease activity and specific organ damage. In depth analysis reveals complex and multiple roles of certain miRNAs in the pathogenesis of SLE. Manipulating miRNA expression shows in vivo therapeutic effects in lupus mouse models. MiRNAs contribute to the immune disorders and organ damage in SLE. MiRNA based biomarkers and therapies have the potential to be viable options for the treatment of SLE.
['Hong|Soon-Min|SM|', 'Liu|Can|C|', 'Yin|Zhihua|Z|', 'Wu|Lingling|L|', 'Qu|Bo|B|', 'Shen|Nan|N|']
D000818:Animals D015415:Biomarkers D006801:Humans D008180:Lupus Erythematosus, Systemic D051379:Mice D035683:MicroRNAs
MicroRNA Systemic lupus erythematosus Biomarker Therapy Lupus nephritis